Equities

PetVivo Holdings Inc

PETV:QBB

PetVivo Holdings Inc

Actions
  • Price (USD)0.55
  • Today's Change0.007 / 1.27%
  • Shares traded14.81k
  • 1 Year change-68.02%
  • Beta2.5821
Data delayed at least 15 minutes, as of Sep 20 2024 20:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PetVivo Holdings, Inc. is a biomedical device company focused on the manufacturing, commercialization and licensing of medical devices and therapeutics for companion animals. The Company has developed a pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the Company’s biomaterials, products, production processes and methods of use. Spryng with OsteoCushion Technology, its flagship product, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses. It also has a pipeline that includes several therapeutic devices for both veterinary and human clinical applications. The Company manufactures its products in an ISO 7 certified clean room manufacturing facility in Minneapolis using its patented and scalable self-assembly production process. The Company may establish strategic out-licensing partnerships.

  • Revenue in USD (TTM)975.28k
  • Net income in USD-10.11m
  • Incorporated2009
  • Employees20.00
  • Location
    PetVivo Holdings Inc5251 Edina Industrial BlvdEDINA 55439United StatesUSA
  • Phone+1 (952) 217-4952
  • Fax+1 (775) 884-9383
  • Websitehttps://petvivo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bioelectronics Corp1.61m-289.82k7.41m9.00------4.60-0.00002-0.000020.00007-0.00066.329.2014.53---113.86-383.59----49.4351.48-18.01-143.480.0099-0.4909----94.01-5.0975.01------
Nexalin Technology Inc150.16k-5.40m7.42m6.00--3.93--49.39-0.7261-0.72610.02020.17810.04460.167911.5325,026.67-160.37---202.23--82.94---3,598.50--4.89--0.00---91.62---173.80------
Neurometrix Inc4.38m-7.94m7.74m26.00--0.445--1.77-5.50-5.502.918.580.21021.158.53168,600.80-38.06-23.24-40.80-27.2660.1959.17-181.03-48.8810.71--0.00---28.52-18.18-47.84--5.03--
Dror Ortho-Design Inc0.00-5.63m7.88m4.00--4.75-----0.012-0.0120.000.00340.00-------577.48-140.50-1,394.24---------118,188.00----0.00-------1,896.02------
Guided Therapeutics Inc38.00k-2.39m9.05m4.00------238.11-0.0444-0.04440.0007-0.08290.02110.03658.449,500.00-120.81-136.13----42.1129.39-5,721.05-3,666.670.0679-7.58----653.8511.4524.40------
Precipio Inc16.72m-3.83m9.29m51.00--0.7603--0.5556-2.68-2.6811.738.240.908917.1216.80327,843.10-20.82-44.98-27.94-58.6839.0828.80-22.90-118.070.590-192.590.0517--61.4639.6252.04--5.37--
ALR Technologies Inc9.49k-8.00m10.17m6.00------1,071.39-0.0147-0.01470.00002-0.04760.0358----1,581.67-3,015.28-12,861.64----62.49---84,283.24-406,011.30---0.8626---------42.72------
Bionoid Pharma Inc0.001.35m10.80m13.000.1764--7.98--1.131.130.00-0.1744-----------506.64--------------327.24---------31.55--26.01--
PetVivo Holdings Inc975.28k-10.11m10.86m20.00--13.03--11.14-0.6705-0.67050.0620.04170.32570.40516.3748,764.00-337.63-230.77-589.09-467.9983.6066.21-1,036.50-1,501.440.455-1,075.050.0221--5.62---25.67--23.91--
Vivos Therapeutics Inc14.02m-12.05m10.95m114.00--1.73--0.7811-6.98-6.986.881.870.9477--38.84123,000.00-81.41-89.72-166.05-149.7060.0870.20-85.90-113.15----0.00---13.8729.4843.04---8.48--
Scientific Industries Inc10.45m-7.76m12.29m63.00--1.05--1.18-0.9231-0.92311.171.110.73431.139.08165,942.90-54.50---62.11--45.41---74.22--3.15--0.00--------------
STRATA Skin Sciences Inc32.73m-8.31m12.35m99.00--1.09--0.3772-2.37-2.379.352.710.69063.477.81330,606.10-17.54-11.48-24.26-16.5554.3061.28-25.40-17.700.9176-2.690.6141---7.752.24-95.17--23.29--
Dalrada Financial Corporation32.16m-21.34m12.41m0.00--1.41--0.386-0.2388-0.23880.35730.0911.098.863.37---75.10-80.63-239.06--30.1139.23-68.78-63.941.24-21.540.3452--54.35---43.94------
Applied DNA Sciences Inc3.40m-7.52m12.46m53.00--1.01--3.67-11.86-11.862.181.200.20926.835.6864,114.15-45.51-88.57-55.20-121.9125.0444.35-217.48-113.263.76--0.00---26.4327.92-18.73--33.80--
QT Imaging Holdings Inc0.00-4.02m12.86m----0.5917-----0.3999-0.39990.001.010.00-------12.32---16.60--------------0.3042-------45.07------
Data as of Sep 20 2024. Currency figures normalised to PetVivo Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Ridgewood Investments LLCas of 30 Jun 2024170.000.00%
Regal Investment Advisors LLCas of 30 Jun 20240.000.00%
Boothbay Fund Management LLCas of 30 Jun 20240.000.00%
Cetera Investment Advisers LLCas of 30 Jun 20240.000.00%
Delos Wealth Advisors LLCas of 30 Jun 20240.000.00%
Asset Dedication LLCas of 30 Jun 20240.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 20240.000.00%
Tower Research Capital LLCas of 30 Jun 20240.000.00%
Bard Associates, Inc.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.